Form 4: Director Karen Prange Receives Outset Medical Equity Grant

Outset Medical director Karen Prange was granted 10,667 restricted stock units as part of standard equity compensation.

Summary

• Director Karen Prange acquired 10,667 shares of Outset Medical (OM) common stock.
• The acquisition was in the form of restricted stock units (RSUs) granted at a price of $0.0.
• Following this transaction, the reporting person's total beneficial ownership increased to 29,334 shares.
• The RSUs are subject to a vesting schedule tied to the one-year anniversary of the grant or the next annual meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Standard market risks associated with equity ownership in a publicly traded medical device company.

Future Outlook

The RSUs vest on the earlier of the one-year anniversary of the grant or the date of the issuer's next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practices designed to incentivize long-term oversight and alignment with shareholder value.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation practices for mid-cap medical technology companies.
• The vesting schedule aligns with typical annual director compensation cycles observed in the healthcare sector.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity grant to a director.

Next Steps

• Vesting of the 10,667 RSUs upon the earlier of the one-year anniversary or the next annual meeting.

Key Dates

Keywords

Outset Medical, OM, Form 4, Insider Trading, Equity Compensation, Director